Tirzepatide represents a distinct chapter in incretin pharmacology research: a single peptide engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. For research laboratories, it is a case study in multi-receptor peptide design, biased agonism, and the analytical challenges of characterizing long, lipidated synthetic peptides. This article covers its structure, […]
